InMed Pharmaceuticals Inc.

A Vancouver-based pharma company developing drugs from rare cannabinoids (CBN, CBG, CBC) that plants produce in tiny quantities — using biosynthesis to manufacture them at pharmaceutical scale.

• 🧬 BioSynt platform synthesizes rare cannabinoids chemically, bypassing the limitations of plant extraction entirely
• 💊 INM-755 (cannabinol cream) is in clinical trials for epidermolysis bullosa, a rare and severe skin blistering disease
• 🔬 Rare cannabinoid focus sets InMed apart from the dozens of companies racing to develop CBD- or THC-based drugs